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Schistosomiasis, or bilharzia, is a common intravascular
infection caused by parasitic Schistosoma trematode worms.1 2
A systematic review and meta-analysis published in 2006
estimated that more than 200 million people are infected across
Africa, Asia, and South America, and close to 800 million are
at risk of infection.3 Meta-analyses have estimated that the
current disease burdenmay exceed 70million disability adjusted
life years.4 5 The disease is also associated with anaemia, chronic
pain, diarrhoea, exercise intolerance, and undernutrition, and
female urogenital schistosomiasis may be a risk factor for HIV
infection.4w15 Figure 1⇓ shows the proposed pathway of
schistosomiasis associated disease and disability derived from
meta-analyses of disability-related outcomes.4
Schistosome transmission requires contamination of water by
faeces or urine containing eggs, a specific freshwater snail as
intermediate host, and human contact with water inhabited by
the intermediate host snail.1 2 Schistosomiasis transmission is
highly dependent on environmental conditions, particularly
those affecting the snail host. Climate change will alter aquatic
environments and subsequently the transmission and distribution
of waterborne diseases.6w2
In this review, we introduce the schistosome parasites and
describe the pathophysiology and the clinical disease they cause.
We discuss current diagnostic tools and the management of
schistosomiasis, based on evidence from studies of both high
and lower quality as well as information from current
international guidelines.
Where and how is schistosomiasis
acquired?
The global distribution of schistosomiasis is shown in figure
2,⇓ which is based on WHO statistics. 1The majority of
infectionswith Schistosoma haematobium, Schistosomamansoni
and Schistosoma intercalatum are found in sub-SaharanAfrica.1S
mansoni remains endemic in parts of Brazil, Venezuela, and
the Caribbean. Schistosoma japonicum infection occurs in the
People’s Republic of China, the Philippines, and small pockets
in Indonesia, despite substantial and largely successful control
measures.1 2Schistosoma mekongi is found along the Mekong
River in Cambodia and Lao People’s Democratic Republic
(Laos).1-7 Infection is usually acquired through activities such
as swimming, bathing, fishing, farming, and washing clothes.
Important transmission sites include Lake Malawi and Lake
Victoria in Africa, the Poyang and Dongting Lakes in China,
and along the Mekong River in Laos. The life cycle of the
schistosome is depicted in figure 3⇓. Intermediate snail hosts
are more likely to inhabit still to moderately flowing fresh water
and infection increases exponentially with length of time in
contact with water, peaking at 30 minutes.w3
What are the clinical features of
schistosomiasis?
Schistosomiasis progresses in three distinct phases: acute,
chronic, and advanced disease.
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Summary points
Schistosomiasis, or bilharzia, is a common intravascular infection caused by parasitic Schistosoma trematode worms
It is prevalent in Africa, the Middle East, South America, and Asia
Acute schistosomiasis, or Katayama syndrome, can present as fever, malaise, myalgia, fatigue, non-productive cough, diarrhoea (with
or without blood), haematuria (S haematobium), and right upper quadrant pain
Chronic and advanced disease results from the host’s immune response to schistosome eggs deposited in tissues and the granulomatous
reaction evoked by the antigens they secrete
S mansoni, S japonicum, S intercalatum, and S mekongi cause intestinal disease; S haematobium causes urinary disease
Neuroschistosomiasis is arguably the most severe clinical syndrome associated with schistosome infection
Microscopic examination of excreta (stool, urine) is the gold standard diagnostic test but requires the adult worms to be producing eggs;
serological tests can diagnose less advanced infections
Praziquantel 60 mg/kg in three doses over one day (S japonicum and S.mekongi); and 40 mg/kg in doses over one day (S mansoni, S
haematobium, S intercalatum) remains the treatment of choice although others are being investigated
Preventive chemotherapy is with a single oral dose of praziquantel 40 mg/kg
Sources and selection criteria
Information for this clinical review was obtained from personal reference archives, personal experience, and extensive literature searches
of the PubMed and Cochrane databases. We sourced English language papers that were fully published mainly between 2000 and September
2010 using appropriate index terms. Keywords included: “schistosomiasis”; “human schistosomiasis”; “schistosoma”; “schistosomiasis” with
“diagnosis”, “treatment”, “acute”, “clinical”, “review”, and “meta analysis”; and “schistosoma” with “diagnosis”, “treatment”, “acute”, “clinical”,
“review”, “meta analysis”; and “schistosome-induced pathophysiology clinical disease”.
Early manifestations
Rash
A maculopapular eruption, comprising discrete erythematous
raised lesions that vary in size from 1 cm to 3 cm, may arise at
the site of percutaneous penetration by schistosome cercariae.
(fig 4⇓) Migrants or tourists infected for the first time may
develop a skin reaction within a few hours, although a rash may
appear up to a week later. This is less severe than, although
similar to, “swimmers itch”, which is not a sequela of acute
schistosomiasis but rather an immune reaction that develops in
sensitised people when they are reinfected by species of
schistosomes that do not colonise humans.1 2
Acute schistosomiasis (Katayama syndrome)
The symptoms of acute schistosomiasis are mediated by the
immune complexw4-w7 and usually begin with the deposition of
schistosome eggs into host tissues. Symptoms may include
fever, malaise, myalgia, fatigue, non-productive cough,
diarrhoea (with or without the presence of blood), haematuria
(S haematobium), and right upper quadrant pain. Acute
schistosomiasis is seen in people who are infected for the first
time when travelling to endemic areas. In the case of S
japonicum it is also associated with either a superinfection or
a hypersensitivity reaction in previously infected people.8
Differential diagnoses include gastroenteritis, hepatitis A, B,
and C, HIV, salmonellosis, and urinary tract infection.8
Chronic and advanced disease
Mature, patent, schistosome infections are associated with a
chronic local inflammatory response to schistosome eggs trapped
in host tissues, which may lead to inflammatory and obstructive
disease in the urinary system (S haematobium) or intestinal
disease, hepatosplenic inflammation, and liver fibrosis (S
mansoni, S intercalatum, S japonicum and S mekongi).1 2
Immunopathological studies have shown that schistosomiasis
results from the host’s immune response to schistosome eggs
(fig 5⇓) and the granulomatous reaction evoked by the antigens
they secrete.1-10 Granulomas, which develop at the sites of
maximal accumulation of eggs, destroy the eggs but result in
fibrosis in host tissues.1 2w8-w12 Granuloma formation and the
local inflammatory response mediated by CD4+ T-helper-2
lymphocytes help facilitate the passage of eggs into the lumen
of the gut or urinary tract.w13
Gastrointestinal and liver disease
Eggs retained in the gut wall induce inflammation, hyperplasia,
ulceration, micro-abscess formation, and polyposis. Symptoms
of gastrointestinal disease include colicky hypogastric pain or
pain in the left iliac fossa, diarrhoea (particularly in children)
that may alternate with constipation, and haematochezia (blood
in the faeces). Severe chronic intestinal disease may result in
colonic or rectal stenosis. Colonic polyposis may manifest as a
protein losing enteropathy. An inflammatory mass in the colon
may even mimic cancer.1 2
Eggs of S mansoni and S japonicum embolise to the liver, where
the granulomatous inflammatory response induces presinusoidal
inflammation and periportal or clay-pipe-stem fibrosis,1 2which
population studies have shown are associated with sustained
heavy infection and can take many years to develop.1 2w14-w19
Hepatomegaly, secondary to granulomatous inflammation,
occurs early in the evolution of chronic disease. Periportal
collagen deposits lead to the progressive obstruction of blood
flow, portal hypertension, and ultimately varices, variceal
bleeding, splenomegaly, and hypersplenism.1 Periportal fibrosis
can be seen on ultrasonography, computed tomography, or
magnetic resonance imaging and is characteristic of
schistosomiasis.
Genitourinary disease
Urinary tract disease develops after infection with S
haematobium and granulomatous inflammation in response to
deposition of eggs in tissues.1 2w10 Haematuria, appearing 10-12
weeks after infection, is the first sign of established disease (fig
4). Dysuria and haematuria occur in early and late disease. Late
disease manifestations also include proteinuria (often nephrotic
syndrome), bladder calcification, ureteric obstruction, secondary
bacterial infection in the urinary tract, renal colic,
hydronephrosis, and renal failure.1 2w10 Structural abnormalities
of the urinary tract may occur in children.1 2w20 Cystoscopy may
reveal characteristic “sandy patches,” which are areas of
roughened bladder mucosa surrounding egg deposits.1 2
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Epidemiological studies have associated chronic urinary
schistosomiasis with squamous cell carcinoma of the bladder
in Egypt and other parts of Africa.w21-w25 In Egypt, the incidence
of bladder cancer has decreased in line with decreasing
prevalence of schistosomiasis over the past few decades.w26w271 2S
haematobium bladder squamous cell carcinomas tend to be well
differentiated and metastasise locally.w21-w27 Nitrosamines,
β-glucuronidase, and inflammatory gene damage have been
proposed as possible carcinogenic factors.1 2w25However, another
explanation is that schistosomiasis lesions intensify the exposure
of the bladder epithelium tomutagenetic substrates from tobacco
or chemicals.1w22S haematobium causes genital disease in about
a third of infected women.2 Vulval schistosomiasis may also
facilitate the transmission of HIV, according to clinical findings;
pathophysiological and immunological data, and epidemiological
surveillance information.1 2 w24 w28 w29
Additional morbidity associated with
schistosomiasis
Neuroschistosomiasis (fig 6⇓, box 1) is arguably the most severe
clinical outcome associated with schistosome infection and
includes signs and symptoms of increased intracranial pressure,
myelopathy, and radiculopathy.1-12w30 Case studies suggest that
neurological complications early in the course of infection are
due to egg deposition following aberrant migration of adult
worms to the brain or spinal cord. The mass effect of thousands
of eggs and large granulomas in the brain or spinal cord underpin
neuroschistosomiasis. Complications of cerebral disease include
encephalopathy with headache, visual impairment, delirium,
seizures, motor deficit, and ataxia; spinal symptoms comprise
lumbar pain, lower limb radicular pain, muscle weakness,
sensory loss, and bladder dysfunction.11 12 Myelopathy (acute
transverse myelitis and subacute myeloradiculopathy) of the
lumbosacral region is the most commonly reported neurological
manifestation of both S mansoni and S haematobium infection,
whereas acute encephalitis of the cortex, subcortical white
matter, basal ganglia, or internal capsule is reportedly typical
of S japonicum.11 12
Population studies of children have shown that schistosome
infection can cause growth retardation and anaemia, as well as
possible cognitive and memory impairment, which limits their
potential.1-13 Randomised controlled trials have shown that
successful treatment in children leads to appreciable but
incomplete catch-up growth and improvement in haemoglobin
levels.1-13w26-w31 Schistosome infection seems to adversely affect
maternal health and the unborn foetus. Chronic infection with
S mansoni and (rarely) S haematobium, but not S japonicum,
may cause pulmonary hypertension, cor pulmonale,
glomerulonephritis, or transverse myelitis.w31-w36
How is schistosomiasis diagnosed?
Box 2 outlines the approach to making a positive diagnosis of
schistosomiasis including important questions to ask onmedical
history, specific signs to look for on physical examination, and
relevant supportive laboratory and radiological investigations
that should be undertaken. Figure 7⇓ presents an algorithm for
diagnosis andmanagement.Microscopic examination of excreta
(stool, urine) remains the gold standard test for diagnosis of
schistosomiasis albeit with some limitations.1 Schistosome eggs
are easy to detect and identify on microscopy owing to their
characteristic size and shape with a lateral or terminal spine (fig
8⇓). Wait at least two months after the last known freshwater
contact before looking for eggs, as a patent infection takes this
long to start producing eggs.1 2w37-w42
S mansoni, S japonicum, S mekongi, and S intercalatum
(intestinal schistosomiasis) are diagnosed by observing even a
single egg in thick smears of stool specimens (2-10 mg) with
or without suspension in saline. The extent to which eggs are
shed varies and as many as three specimens may be needed to
make a diagnosis in some patients. Formalin based techniques
for sedimentation and concentration may increase the diagnostic
yield1 in patients with a light infection, such as returned
travellers.w43 The rapid, simple, and inexpensive Kato-Katz thick
smear stool examination—recommended byWHO for intestinal
schistosomiasis when the intensity of infection is high—is
widely used in field studies, and requires 40-50 mg of faeces.14
It has specificity of 100% but its sensitivity varies with
prevalence and intensity of infection, as well as with the number
of stool specimens collected and slides prepared for
microscopy.w44-w47For example, one diagnostic studyw44 showed
that the sensitivity increased from 85% for one stool to 100%
for four stools, while anotherw45 showed that the sensitivity
increased from 70% for one smear to 92% for four smears.
Several population based studies have shown that mean egg
burdens correlate with the mean severity of disease.1 2w46 w47
However, it is not necessary to quantify the egg burden in order
to provide clinical care.
S haematobium eggs are released in urine and are detected by
microscopy in a urine sample concentrated by sedimentation,
centrifugation, or filtration and forced over a paper or
nitrocellulose filter.1 2 A urine sample is ideally collected
between 10 am and 2 pm to coincide with the maximum
excretion of eggs. Self reported blood in the urine and
microhaematuria on reagent strips indicates potential infection
in those living in endemic areas.w48-w50
Specific and highly sensitive PCR based assays have been
developed for the detection of schistosome DNA in faeces or
sera and plasma.15-17 This approach has the potential to provide
a test for diagnosing schistosomiasis in all phases of clinical
disease, including the capacity to diagnose Katayama syndrome
and active disease, and for the evaluation of treatment. The
miracidium hatching test has been used by public health workers
in China to rule out S japonicum infection.2w51 Eggs are
concentrated by placing faeces in a nylon tissue bag suspended
in distilled water. Miracidia that hatch are visualised
macroscopically, and their presence is diagnostic of infection.
A biopsy of bladder or rectal mucosa may be considered for
diagnosis in patients with a typical clinical presentation of
schistosomiasis but with no eggs detectable in urine or faeces.2
Indirect methods for diagnosing schistosome infection using
clinical, subclinical, or biochemical morbidity markers are not
specific given the generalised presentation of schistosomiasis.
Current indirect methods include the use of clinical assessment
of the patient coupled with ultrasound, liver biopsy, and
subsequent histological examination and the measurement of
biochemical markers.1 2 Case studies have suggested that
additional supportive laboratory evidence of schistosomiasis
might include evidence of peripheral blood eosinophilia,
anaemia (iron deficiency anaemia, anaemia of chronic disease,
or macrocytic anaemia), hypoalbuminaemia, raised
concentrations of urea and creatinine, and
hypergammaglobulinaemia.1 2 Splenomegaly develops in some
patients with pancytopenia.1 Biochemical markers of liver
fibrosis (pro-collagen peptides type III and IV, the P1 fragment
of laminin, hyaluronic acid, fibrosin, tumour necrosis factor
αR-II, and sICAM-1) measured in serum have potential to
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Box 1: Neuroschistosomiasis
Diagnosis
The finding of eggs in the stool or positive serology provides supportive but not direct evidence of schistosomal involvement in the central
nervous system. A positive diagnostic finding coupled with neuroimaging and neurological symptoms should place neuroschistosomiasis
high on the list of differentials. A definitive diagnosis can only be ascertained with histopathological study at biopsy or at necropsy,
showing schistosome eggs and granulomas.
Signs and symptoms
Focal or generalised epilepsy (S japonicum)
Transverse myelitis (S mansoni and S haematobium)
Nystagmus
Speech disturbances
Motor weakness (hemiplegia, paraplegia, or quadriplegia)
Papilloedema
Lumbar pain and lower limb radicular pain (S mansoni and S haematobium)
Sensory loss (T12 to L1)
Bladder dysfunction
Neuro-imaging
Computerised tomography
Magnetic resonance imaging
Myelography
Management
Consult with a neurologist and an infectious disease physician
Treatment with corticosteroids and anticonvulsants within two months of infection
Praziquantel chemotherapy two months after known water contact
Box 2: Key indicators for positive diagnosis of schistosomiasis
Medical history
Have you travelled to or emigrated from an endemic country recently? If so from where?
Have you been in contact with a freshwater source (such as lakes, rivers, or streams)?
(Patients returning/emigrating from Africa or the Middle East may have either intestinal or urinary schistosomiasis and those from Asia
or South America may have intestinal schistosomiasis)
Physical examination
An urticarial rash (maculopapular lesions) may be present where the cercariae penetrated the skin (discrete erythematous raised lesions
that vary in size from 1-3 cm)
On palpation of the abdomen, hepatomegaly (tender left lobe) and in about a third of patients splenomegaly may be detected
Auscultation of the lungs frequently detects dry or moist rales during the acute phase
Generalised lymphadenopathy may be present
Laboratory investigations
Stool/urine examination for schistosome eggs
Full blood count: eosinophilia (>80% of patients) with acute infections; anaemia and thrombocytopenia may be present in chronic and
advanced schistosomiasis
Coagulation profile: prolonged prothrombin time, indicated by an increased international normalised ratio, may be evident in chronic
and advanced cases
Urea, electrolytes, and liver function: raised urea and creatinine may be evident; and hyperglobulinaemia and hypoalbuminaemia may
be present in chronic and advanced schistosomiasis
Serology: may be diagnostic in patients in whom no eggs are present, such as those with Katayama syndrome
Rectal or bladder biopsy for the identification of eggs may be performed if stool or urine are egg-negative but schistosomiasis is still
suspected
Radiology
Chest radiograph: pulmonary infiltrates are common in acute cases (Katayama syndrome)
Abdominal ultrasound: can establish extent of liver and spleen pathology in intestinal schistosomiasis
Pelvic ultrasound: can establish extent of bladder, ureteral, and renal pathology in urinary schistosomiasis
provide a highly sensitive and cost-effective method for
assessment of schistosome induced fibrosis.18w55-w54 A biopsy of
the liver may be necessary in some patients with co-infection
(eg with hepatitis virus).1 Liver involvement in patients with
schistosomiasis may be suggested by the characteristic
appearance of the organ on abdominal imaging.1 2
Antibody detection can be useful in a few specific
circumstances, but its application is limited.1-19 A positive
serological test may be diagnostic in patients who are not
excreting eggs, such as those with Katayama syndrome.
Serological testing can be useful in field studies for defining
regions of low level endemicity, where individual patients have
low egg burdens, and may also be beneficial for determining
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whether infection has re-emerged in a region after an apparently
successful control programme. It is important for diagnosis in
travellers. Commercially available immunodiagnostic kits are
less sensitive thanmultiple faecal examinations and less specific,
owing to antibody cross-reactivity with antigens from other
helminths.1 19w55-w57 Most techniques detect IgG, IgM, or IgE
against soluble worm antigen or soluble egg antigen by
enzyme-linked immunosorbent assay (ELISA), indirect
haemagglutination, or immunofluorescence.1 2 A cercarial
antigen ELISA equivalent to the soluble egg antigen assay has
been developed for serodiagnosis of schistosomiasis.20
Detection of circulating adult worm or egg antigens with labelled
monoclonal or polyclonal antibodies in serum, urine, or sputum
in infected individuals is another promising technique that may
eventually supersede traditional diagnostic methods.1 2 A
commercially produced diagnostic test—the urine circulating
cathodic antigen strip—is available for detection of
schistosomiasis.21 Surveillance studies and cross sectional
surveys have shown that circulating cathodic antigen may be
useful for screening for both S haematobium and S mansoni
infections in the field but, to date, seems not to have sufficient
sensitivity and/or specificity for definitive diagnosis.w58 w59
How is schistosomiasis treated?
Praziquantel
Randomised controlled trials have shown that praziquantel, a
pyrazinoisoquinoline derivative, is a safe and effective oral drug
that is active against all schistosome species.22 23 The drug is
absorbed well but undergoes extensive first pass hepatic
clearance. It is secreted in breast milk and is metabolised by the
liver, and its metabolites (which are inactive) are excreted in
the urine. The drug acts within one hour of ingestion although
its precise action on adult worms is unknown. Laboratory studies
have shown that it causes tetanic contractions and tegumental
vacuoles, which cause worms to detach from the walls of veins
and die. Schistosome calcium ion channels have been indirectly
identified as the molecular target of praziquantel. In animal
models, the presence of host antibodies is critical for efficacy.1-23
Randomised controlled trials have also shown that the effective
praziquantel dosage regimen is 60mg/kg orally in divided doses
over one day (3 x 20 mg/kg doses 4-hourly or 2 x 30 mg/kg
either 4-hourly or 6-hourly) for S japonicum and S mekongi,
and 40mg/kg orally in divided doses over one day (2 x 20mg/kg
doses 4-hourly) for S mansoni, S haematobium, and S
intercalatum.1-24 (table⇓). However, a single 40 mg/kg dose is
administered with 66-95% efficacy for epidemiological studies
and population-based preventive chemotherapy control
programmes.2w60 Efficacy of 95-100% can be achieved with
re-treatment four to six weeks later25 and this second dose is
advisable, especially if eosinophilia and a high antibody titre
persist after primary treatment. Praziquantel has few side effects
other than transient nausea, dizziness, rash, and pruritus, which
are thought to be associated with the consequences of worm
death rather than the drug itself.1-23 It can be used to treat young
children (>4 years old) and pregnant women if breastfeeding is
discontinued on the day of treatment and for the next 72 hours.8
In patients with concurrent schistosomiasis and Taenia solium
cysticercosis, praziquantel can cause irreparable eye lesions
owing to the death of Taenia parasites in the ocular region, and
it may also induce seizures and/or cerebral infarction owing to
the intense inflammatory reactions that can be initiated by the
dying Taenia cysts.w61
Experimental laboratory studies in mice have indicated,
somewhat controversially, that resistance to praziquantel may
be emerging in Africa, where there has been heavy exposure to
the drug, and where, worryingly, there are reports of S mansoni
and S haematobium infections that are not responsive.1w62 w63
Laboratory evidence suggests that drug tolerant schistosome
worms may have an altered tegumental architecture, which
could limit the effectiveness of the drug. So far, however,
patients in many communities have undergone multiple courses
of treatment over a period of 10 or more years without
demonstrable loss of efficacy. Because worm reproduction in
the mammalian host is sexual and the generation time is
relatively long, resistance is likely to take many years to become
an important clinical and public health issue. Nevertheless,
resistance against praziquantel in the future cannot be ruled out
and research should continue on developing alternative
drugs—such as
4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide, a new
compound that has been shown to inhibit a crucial parasite
enzyme, thioredoxin glutathione reductase).26
Adjuvant treatment
Corticosteroids (for example, prednisone 1.5-2.0 mg/kg per day
for three weeks) are used to treat Katayama syndrome within
two months of freshwater contact8w55 w64 (table) and for the
treatment of schistosomal encephalopathy during the oviposition
(egg laying) stage.11 12 Corticosteroids and anticonvulsants may
be needed as adjuvants to praziquantel in neuroschistosomiasis,
which needs specialised care.1 Corticosteroids help to alleviate
acute allergic reactions and prevent mass effects caused by
excessive granulomatous inflammation in the central nervous
system. Anticonvulsants are used to treat seizures associated
with cerebral schistosomiasis but lifelong use is rarely indicated
(table). Surgery should be preserved for particular patients, such
as those with evidence of medullary compression and for those
who deteriorate, despite clinical treatment.11 12 A
ventriculoperitoneal shunt and corticosteroids are required to
treat hydrocephalus and intracranial hypertension in cerebral
schistosomiasis.11 12
Other antiparasitic agents
Other drugs used to treat schistosomiasis are oxamniquine for
S mansoni and metrifonate for S haematobium, but neither is
effective against S japonicum.1 2 A recent randomised,
exploratory open label trial of mefloquine-artesunate showed
promising efficacy against S haematobium and further
investigation of this approach is warranted.27
Praziquantel cannot be used for chemoprophylaxis because of
its short half-life (1-1.5 hours) and because it cannot kill
schistosomula (migrating larvae) that are three to 21 days old.
Artemether is effective against juvenile schistosomes during
the first 21 days of infection in animals and humans28 and, if
given every two weeks, should kill all immature schistosomula.
It has been used as a chemoprophylactic in schistosomiasis
endemic areas for those at high risk of infection, such as flood
relief workers and fishermen in China (table).29 The doses
required are lower than those for the treatment of malaria, but
it is unlikely that artemether will be used routinely in regions
where malaria is endemic because of the risk of selecting
artemether resistant Plasmodium falciparum. Randomised
controlled trials have shown that combination therapy with
praziquantel plus artemether is safe and results in higher rates
of worm reduction than praziquantel alone.28 29 However, a
randomised, double blind, placebo controlled trial that evaluated
combined chemotherapy for acute schistosomiasis japonica in
China failed to show improved treatment efficacy compared
with praziquantel alone.24 Standard treatment with praziquantel
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was also more effective than artesunate with sulfalene plus
pyrimethamine in the treatment of children with S mansoni
infection in western Kenya.30 It is unclear, therefore, whether
artemether based combination therapy has a role in the treatment
of schistosomiasis.31 w65
What are the future challenges?
The challenge for researchers who aim to improve the diagnosis
and management of schistosomiasis will be to find a way to
respond to environmental changesw2 and to the threat of
praziquantel resistance. New diagnostic procedures that are
simple, rapid, and able to diagnose light infections (such as
simple dipstick tests and PCR-based assays) need further
development, as do new drugs that act effectively on both adult
and larval schistosomes, and vaccines that target either the
human host or, in the case of S japonicum or S mekongi, the
animal reservoir hosts.
An integrated approach to the management of schistosomiasis32
w66 that offers treatment alongside measures to reduce
transmission by snail control (focal mollusciciding and
environmental modification), health education and promotion,
improved sanitation, and vaccination is the key to sustainable
long term control of schistosomiasis.32
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Additional educational resources
Introduction to schistosomiasis (www.path.cam.ac.uk/~schisto/schistosoma/index.html)—Outline from the Schistosomiasis Research
Group, University of Cambridge
Health topics: schistosomiasis (www.who.int/topics/schistosomiasis/en)—Information from the World Health Organization
Parasites—schistosomiasis (www.cdc.gov/ncidod/dpd/parasites/schistosomiasis/factsht_schistosomiasis.htm)—Fact sheet from the US
Centers for Disease Control and Prevention
Schistosomiasis (www.medicinenet.com/schistosomiasis/article.htm)—Information for patients from MedicineNet
A patient’s perspective
I am a 26 year old driver from Yueyang, China. One Sunday last summer, I drove to the Dongting Lake and fished and swam for 30 minutes.
Twenty five days later, I developed a fever and cough and had a distended abdomen and diarrhoea. I was tired and had little appetite. On
the third day of fever I attended a private hospital in Yueyang city. A chest x ray suggested a lung infection. I was treated for four days with
antibiotics and intravenous drips, but my condition did not improve. At another local hospital, I was diagnosed with acute schistosomiasis.
I returned to Yueyang to attend a special schistosomiasis hospital. Schistosome eggs were found in my stool and my blood reacted to
substances in schistosome eggs. X rays showed fluid in my left lung, and my liver and spleen were enlarged. Acute schistosomiasis was
confirmed. I was told all my problems were caused by Schistosoma japonicum and its eggs. I was prescribed a drug called praziquantel and
took the tablets three times a day after meals, three pills each time, for six days. My fever was highest (41.5ºC) on the second day of my
course of praziquantel. A special injection to lower my temperature was given to me and it worked well. I was discharged from hospital two
days after I finished taking the drug. My stool, re-checked 10 and 20 days later, showed no more eggs. After three months, I feel well now.
Mr Yang, Yueyang, Hunan Province, People’s Republic of China
Table
Table 1| Treatment and prophylaxis for schistosomiasis. Adapted from Ross et al8 with permission from Elsevier
Use in special groups
Comments
Main
contraindicationChildrenBreast feedingPregnancyDosage regimenDrug
Used to treat all schistosomes.
Usually well tolerated. Caution
while driving or performing other
tasks requiring alertness on the
day of treatment or the day after
Hypersensitivity,
ocular cysticercosis
Safe for age
>4; not
established
for age <4
Discontinue breast
feeding on day of
treatment for up to
72 hours
Category B: usually
safe, but benefits
must outweigh risk
S haematobium, S mansoni, S
intercalatum, 40 mg/kg per day,
two doses a day by mouth; S
japonicum, Smekongi 60mg/kg
per day, three doses a day by
mouth
Praziquantel
Prophylactic against S
haematobium, S mansoni, S
japonicum. Antischistosomula
properties
HypersensitivitySafeNo data, not
recommended
No data, not
recommended
S haematobium, S mansoni, S
intercalatum, S japonicum, S
mekongi, prophylaxis: 6 mg/kg
every 2-4 weeks by mouth
Artesunate
Used for treatment of Katayama
syndrome (within 2 months of
water contact) and treatment for
sequelae of
neuroschistosomiasis
ImmunosuppressantSafeUnknown effect, not
recommended
Category C:
unknown effect, not
recommended
Adult: 1.5-2.0 mg/kg per day by
mouth for 3 weeks. Paediatric:
0.05-2.0 mg/kg per day, three
doses a day by mouth
Corticosteroids
(prednisone)
Treatment of seizures
associated with
neuroschistosomiasis
HypersensitivitySafeBenefits must
outweigh risk
Category D: not
recommended
Consult neurologistAnticonvulsants
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Figures
Fig 1 Proposed pathways of schistosomiasis associated disease and disability. Adapted from King et al4 with permission
from Elsevier
Fig 2 Global distribution of schistosomiasis. Adapted from Gryseels et al2 with permission from Elsevier.
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Fig 3 Schistosome lifecycle. Freshwater molluscs act as intermediate hosts and higher order vertebrates as definitive hosts.
Adult male and female worm pairs (slender female schistosome lies within the ventral gynaecophoric canal of the male)
produce numerous eggs, most of which are deposited in the capillaries and tissues of the parasitised target organ and
some of which are excreted via the urine or faeces. The shape of the eggs and the location of their excretion differentiate
the various species. S haematobium inhabits the urinary system and the sacral and pelvic vessels, while intestinal
schistosomes inhabit the intestinal mucosa. Some eggs are carried downstream in the portal circulation and, in the case
of an S mansoni or S japonicum infection, are trapped in the liver. Once excreted, an ovum hatches in contact with fresh
water and a free living motile miracidium is released to infect the specific freshwater snail intermediate host—with Smansoni
this is generally Biomphalaria glabrata (Americas) or B pfeifferi (Africa). After about 30 days infected snails release free
swimming cercariae in response to sunlight. These can penetrate the skin of the mammalian host within 12-24 hours, invade
the lymphatic system, and enter the circulation via the lungs as maturing schistosomula.
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Fig 4Clinical manifestations of acute schistosomiasis. Left: maculopapular rash (www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/
A-F/CercarialDermatitis/body_CercarialDermatitis_il2.htm). Right: chest radiograph showing pulmonary infiltrates. Reproduced
from McManus et al13 with permission from the American Society for Microbiology.
Fig 5 Chronic/advanced schistosomiasis pathology. (A) Characteristic perioval granuloma formed around S japonicum egg
in mouse liver. (B) Granuloma formed around an S mansoni egg in human lung tissue. (C) Retrograde pyelogram showing
right sided ureteric stricture due to infection with S haematobium. (D) Double contrast barium enema of a patient infected
with Smansoni. The right side of the transverse colon (left of image) has a normal smooth mucosal lining. The left transverse
colon, splenic flexure, and descending colon have a fine irregular granular mucosal surface, owing to numerous small
lesions caused by deposition of schistosome eggs. The lesions result in inflammation and erosion of the mucosa. Reprinted
from McManus et al13with permission from the American Society for Microbiology. Courtesy of the Wellcome Trust.
Fig 6 Pathology in neuroschistosomiasis. (A) Unenhanced axial CT scan shows small, oval, hyperdense lesion (black
arrow) in the paraventricular zone, dorsal of the right posterior horn. (B) Axial T2-weighted (2437/90/1 [repetition time/echo
time/excitations]) MRI shows hypointense lesion (white arrow) with small centrally located area of intermediate signal (black
arrow). (C) Coronal contrast-enhanced T1-weighted (600/15/2) MRI shows oval lesion of intermediate signal (arrow) with
ring-like and septum-like contrast enhancement. Reprinted fromMcManus et al13with permission from the American Society
for Microbiology. Courtesy of the Wellcome Trust.
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Fig 7Diagnostic and treatment algorithm. M/C/S=microscopy/culture/sensitivity; O/C/P=ova/cysts/parasites; FBC=full blood
count; UE/LFT=urea, electrolytes, and liver function test; ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; ID
doctor=infectious diseases doctor; KUB=kidney, ureter, and bladder; SCC=squamous cell carcinoma.
Fig 8 Schistosome eggs from species (A) S japonicum, (B) Smekongi, (C) Smansoni, (D) S haematobium,(E)S intercalatum.
Courtesy of the Centers for Disease Control and Prevention, (A, C, D, and E) and www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/
Schistosomiasis_il.htm (B). Reproduced from Ross et al8 with permission from Elsevier.
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